drugset
Drugs / Vestipitant
last change Aug 2012 re-read 2 minutes ago

Vestipitant

also known as GW597599 · GW-597588B · GW597599B · Vestipitant mesilate · VESTIPITANT MESYLATE

Small molecule targets TACR1 via inhibition

Developed for
anxiety disorder · major depressive disorder · sleep disorder · social phobia · tinnitus · sleep disorder, initiating and maintaining sleep
Investigated by
GlaxoSmithKline · Accenture

Trials 8 · a red edge is where a trial was stopped

today NCT01507194 · Ph 2 NCT01290133 · Ph 1 NCT00992160 · Ph 2 NCT00394056 · Ph 2 NCT00600990 · Ph 2 NCT00343707 · Ph 2 NCT00403962 · Ph 2 NCT00048204 · Ph 2
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT01290133 May → Oct 2011 — Accenture Completed No outcome recorded
Phase 27 trials
Phase 2 NCT01507194 Feb → Aug 2012 — Accenture Completed No outcome recorded
Phase 2 NCT00992160 May → Sep 2009 sleep disorder GlaxoSmithKline Completed No outcome recorded
Phase 2 NCT00394056 Dec 2006 → Aug 2009 tinnitus GlaxoSmithKline Completed No outcome recorded
Phase 2 NCT00600990 Dec 2004 → Jul 2006 — GlaxoSmithKline Completed No outcome recorded
Phase 2 NCT00343707 Nov 2004 → Nov 2005 anxiety disorder GlaxoSmithKline Completed No outcome recorded
Phase 2 NCT00403962 Nov 2004 → Aug 2005 social phobia GlaxoSmithKline Completed No outcome recorded
Phase 2 NCT00048204 Nov 2002 → Sep 2003 major depressive disorder GlaxoSmithKline Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00606697 Comparator Dec 2007 → May 2008 sleep disorder, initiating and maintaining sleep GlaxoSmithKline Completed No outcome recorded

Evidence & citations 10 cited values

Every value below carries the sentence it was read from. 10 sources stand behind the page.

FieldValueCited text
Known as Vestipitant “a Single Intravenous Dose of the Captisol™ Formulation of Vestipitant (GW597599) in Healthy Adult Subjects” NCT01290133 ↗
5

“Vestipitant (15mg/Day) for the Treatment of Primary Insomnia” NCT00992160 ↗

NCT00394056 ↗

NCT01507194 ↗

NCT00343707 ↗

NCT00403962 ↗
Known as GW-597588B ChEMBL registry synonym — accepted as the source's own label CHEMBL522987 ↗
Known as GW597599 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00606697 ↗
2

NCT00600990 ↗

NCT01290133 ↗
Known as GW597599B ClinicalTrials.gov intervention name — accepted as the source's own label NCT00048204 ↗
Known as Vestipitant mesilate ChEMBL registry synonym — accepted as the source's own label CHEMBL522987 ↗
Known as VESTIPITANT MESYLATE ChEMBL registry synonym — accepted as the source's own label CHEMBL522987 ↗
Action Inhibit “Neurokinin 1 receptor antagonist” CHEMBL522987 ↗
1

“NK1 receptor antagonist” NCT00394056 ↗
Modality Small molecule — CHEMBL522987 ↗
Route Oral “Oral (25 mg)” NCT00600990 ↗
Target TACR1 “Neurokinin 1 receptor antagonist” CHEMBL522987 ↗